NCT00740805
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 158 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study completion pushed from Oct 22, 2026 to Nov 3, 2027
- Minor Study completion date: Oct 22, 2025 to Oct 22, 2026v117
- Minor Study completion date: Oct 7, 2024 to Oct 22, 2025v114
- Minor Study completion date: Oct 7, 2023 to Oct 7, 2024v109
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
GROUP I: Patients receive veliparib PO every 12 hours on days 1-4 and cyclophosphamide IV over 60 minutes on day 3. GROUP II: Patients receive veliparib PO every 12 hours on days 1-4, cyclophosphamide IV over 60 minutes on day 3, and doxorubicin hydrochloride IV over 15 minutes on day 3. GROUP III: Patients receive veliparib PO every 12 hours on days 1-7, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1. GROUP IV: Patients receive veliparib PO every 12 hours on days 1-14, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride over 15 minutes on day 1. In all groups, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Veliparib
Other: Laboratory Biomarker Analysis, Pharmacological Study
Sites
1 site in 1 country
- Rutgers Cancer Institute of New JerseyNew Brunswick, New Jersey, United States